The integration of liquid biopsy technologies in clinical trials is revolutionizing biomarker discovery and implementation, offering non-invasive insights into tumor biology and therapeutic response. This presentation will explore Wren’s innovative approach to mRNA gene signatures, which provide a robust platform for biomarker identification and validation in diverse oncology indications, including neuroendocrine tumors, prostate cancer, colorectal cancer, lung cancer, pancreatic cancer, melanoma, and multiple myeloma.
Leveraging over 100 years of cumulative experience in biomarkers, translational research, and precision medicine, along with our extensive portfolio of over 115 patents and 60+ clinical studies across 16 countries, we have developed proprietary multigene mRNA assays that capture dynamic gene expression profiles from just 1 mL of whole blood. Our assays encompass 412 cancer-associated genes, allowing for the creation of customized gene signatures tailored to specific clinical needs. Advanced algorithms yield actionable insights with clear binary readouts and precise scoring, enabling real-time monitoring of patient responses and disease progression.
We will discuss the clinical applicability of our novel mRNA gene signatures in enhancing the drug development process, including proof of concept and mechanism studies. By demonstrating their utility in detecting minimal residual disease (MRD), predicting treatment responses, and guiding patient stratification, our assays aim to support personalized treatment strategies and improve clinical outcomes.
Join us to discover how Wren’s innovative liquid biopsy solutions can transform biomarker discovery and implementation in clinical trials, ultimately advancing precision medicine and fostering successful therapeutic development. Don’t miss this opportunity to explore the forefront of non-invasive diagnostics in biopharma!
Speaker
Dr. Abdel Halim, PharmD, PhD, CEO/CSO, Wren Laboratories
Dr. Abdel Halim, a Fulbright Scholar, is an executive and internationally recognized KOL with over three decades of experience in biomarker and precision medicine. Dr. Halim is one of only four lab professionals in the US who are triple board-certified in molecular diagnostics, clinical chemistry and toxicology. He is one of only two worldwide accredited by the FDA as a third-party reviewer of the largest list of IVD 510K submissions.
Dr. Halim has led the biomarkers, translational research and precision medicine aspects in 150+ Phase I-Phase III clinical trials in oncology and other indications. He has led 12 end-to-end registrable CDx programs and implemented LDT-based patient selection in 30+ Phase I-Phase II trials. He has overseen the development and validation of hundreds of assays and has championed two drug and several medical device approvals.
Dr. Halim holds a PharmD, two master’s degrees and a PhD in Cancer Molecular Biology. He has published 75+ articles, three book chapters and a single-author reference book.
Message PresenterWho Should Attend?
This webinar will appeal to professionals in the following fields or those with the following job titles:
- Early Discovery
- Translational Medicine
- Biomarkers
- Precision Medicine and Companion diagnostic departments
- Clinical Study Monitors
- Regulatory Affairs
- LDT (Laboratory Development Test)
What You Will Learn
Attendees will learn about:
- Non-Invasive Insights: Learn how liquid biopsies enable real-time monitoring of tumor biology and treatment responses and can facilitate proof of concept and mechanism studies in biopharma
- Actionable Data: Understand how proprietary algorithms convert complex data into clear insights for clinical decision-making
- Custom mRNA Signatures: Discover the development and clinical applications of multigene mRNA assays for various cancers
- Personalized Medicine: Explore how these assays support tailored treatment strategies, including MRD detection and response prediction
Xtalks Partner
Wren Laboratories
Wren is at the forefront of transforming cancer diagnostics through advanced mRNA technologies. Our pioneering machine learning-based liquid biopsy tests utilize multiplex mRNA expression to revolutionize cancer patient care and enhance clinical trials. Conducted in a CLIA-certified, CAP-accredited, and NYSDOH-licensed laboratory, our tests are governed by a robust quality management system.
Our NETest® and PROSTest® assays are clinically validated as diagnostic and prognostic tools, for detecting minimal residual disease and recurrence, and for predicting responses to radiotherapeutics in neuroendocrine and prostate cancers. These clinical assays, featuring binary readouts, are suited for patient selection and stratification in clinical trials, serving as companion or complementary diagnostics. Their utility extends beyond oncology: the FDA has recently accepted our NETest® for predicting tumorigenesis in a diabetic drug trial, addressing potential pancreatic neuroendocrine differentiation.
Wren’s innovative pipeline includes assays for colorectal, lung, breast, pancreatic, melanoma, and multiple myeloma cancers. Our theranostic applications offer customized multigene mRNA gene signatures for biomarker and target discovery, POC, POM, or pharmacodynamics.
Led by a team of biopharma experts with unparalleled scientific, clinical, operational, and regulatory experience, Wren is dedicated to delivering best-in-class services where every sample counts.
Related Webinars
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account